Evidence map›Paper›PMID 35720141›Full record

ReviewIJID regions2022

The impact of the acceleration of COVID-19 vaccine deployment in two border regions in Oman.

Bader Al Rawahi, Adil Al Wahaibi, Sulien Al Khalili, Ahmed Yar Mohammed Al Balushi, Nawal Al-Shehi, Khalid Al Harthi, Seif Al-Abri

Abstract readReview
In one paragraph

Review in IJID regions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bader Al RawahiDirectorate General for Disease Surveillance and Control, Ministry of Health, PO Box 393, 100, Muscat, Oman.
Adil Al WahaibiDirectorate General for Disease Surveillance and Control, Ministry of Health, PO Box 393, 100, Muscat, Oman.
Sulien Al KhaliliDirectorate General for Disease Surveillance and Control, Ministry of Health, PO Box 393, 100, Muscat, Oman.
Ahmed Yar Mohammed Al BalushiDepartment of Disease Surveillance and Control, Directorate General of Health Services, Al-Buraimi Governorate, Ministry of Health, Buraimi, Oman.
Nawal Al-ShehiDepartment of Disease Surveillance and Control, Directorate General of Health Services, Musandam Governorate, Ministry of Health, Khasab, Oman.
Khalid Al HarthiDirectorate General for Disease Surveillance and Control, Ministry of Health, PO Box 393, 100, Muscat, Oman.
Seif Al-AbriDirectorate General for Disease Surveillance and Control, Ministry of Health, PO Box 393, 100, Muscat, Oman.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Among the challenges to public health systems imposed by coronavirus disease 2019 (COVID-19) have been vaccine scarcity and the prioritization of high-risk groups. Countries have been prompted to accelerate the pace of immunization campaigns against COVID-19 to deploy the immunization umbrella to the largest possible number of target groups. In this paper, we share the perspective of Oman regarding the impact of accelerating the administration of the first dose of the COVID-19 vaccine in one border governorate (Musandam) by comparison to another border governorate (Al-Buraimi) where this approach was not applied. Methods: Daily admissions data (April 10, 2020 to June 24, 2021) and vaccination data (January 1 to June 24, 2021) were collected systematically. For each governorate, the cumulative doses (first and second doses) and vaccination coverage were calculated daily. Results: Within 1 month, first dose vaccination coverage increased from 20% to 58% in Musandam, reducing the incidence of hospital admission by 75%. In comparison, vaccination coverage plateaued at 20% in Al-Buraimi, and the incidence of hospital admission increased by 500%. Conclusions: Given the peculiarity of the geographical location and being the first line of access for imported cases, border regions should be a priority for vaccine deployment as a preventive measure. The two different approaches reported here, implemented in broadly similar cross-border governorates, provide evidence of the significant effect of accelerating the first dose of vaccine in reducing hospitalizations.

Indexed as

Border regionsCOVAXCOVID-19OmanPublic healthVaccination

Identifiers

PMID35720141
PMCPMC8970609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.